Hormone Resistant Prostate Cancer Terminated Phase 1 / 2 Trials for Lenalidomide (DB00480)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Terminated1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01093183Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate CancerTreatment